Aberdeen Group’s Healthpeak Properties DOC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $22.8M | Sell |
1,065,085
-135,995
| -11% | -$2.54M | 0.03% | 406 |
|
|
2026
Q1 | $19.7M | Sell |
1,201,080
-155,526
| -11% | -$2.67M | 0.03% | 434 |
|
|
2025
Q4 | $21.8M | Buy |
1,356,606
+54,914
| +4% | +$968K | 0.03% | 398 |
|
|
2025
Q3 | $24.8M | Sell |
1,301,692
-596,988
| -31% | -$10.7M | 0.04% | 363 |
|
|
2025
Q2 | $32.6M | Sell |
1,898,680
-869,748
| -31% | -$15.4M | 0.06% | 291 |
|
|
2025
Q1 | $55.7M | Sell |
2,768,428
-56,091
| -2% | -$1.13M | 0.11% | 175 |
|
|
2024
Q4 | $56.9M | Buy |
2,824,519
+75,211
| +3% | +$1.63M | 0.11% | 190 |
|
|
2024
Q3 | $62.7M | Buy |
2,749,308
+471,876
| +21% | +$10.2M | 0.11% | 185 |
|
|
2024
Q2 | $44.6M | Buy |
2,277,432
+395,985
| +21% | +$7.56M | 0.09% | 229 |
|
|
2024
Q1 | $35.3M | Buy |
1,881,447
+739,000
| +65% | +$13.4M | 0.07% | 266 |
|
|
2023
Q4 | $22.6M | Sell |
1,142,447
-221,618
| -16% | -$3.9M | 0.05% | 361 |
|
|
2023
Q3 | $25M | Sell |
1,364,065
-210,946
| -13% | -$4.33M | 0.06% | 277 |
|
|
2023
Q2 | $31.7M | Buy |
1,575,011
+209,566
| +15% | +$4.35M | 0.07% | 252 |
|
|
2023
Q1 | $30M | Buy |
1,365,445
+124,976
| +10% | +$3.1M | 0.08% | 264 |
|
|
2022
Q4 | $31.1M | Buy |
1,240,469
+57,434
| +5% | +$1.4M | 0.08% | 258 |
|
|
2022
Q3 | $27.1M | Buy |
1,183,035
+636,402
| +116% | +$16.8M | 0.08% | 266 |
|
|
2022
Q2 | $14.2M | Buy |
546,633
+88,324
| +19% | +$2.68M | 0.04% | 355 |
|
|
2022
Q1 | $16M | Buy |
458,309
+15,267
| +3% | +$514K | 0.04% | 347 |
|
|
2021
Q4 | $16M | Buy |
443,042
+9,097
| +2% | +$314K | 0.04% | 389 |
|
|
2021
Q3 | $14.6M | Buy |
433,945
+43,619
| +11% | +$1.54M | 0.03% | 417 |
|
|
2021
Q2 | $13M | Buy |
390,326
+49,673
| +15% | +$1.67M | 0.03% | 444 |
|
|
2021
Q1 | $10.8M | Buy |
340,653
+50,873
| +18% | +$1.55M | 0.02% | 480 |
|
|
2020
Q4 | $8.76M | Buy |
289,780
+23,322
| +9% | +$679K | 0.02% | 494 |
|
|
2020
Q3 | $7.23M | Sell |
266,458
-7,622
| -3% | -$209K | 0.02% | 488 |
|
|
2020
Q2 | $7.55M | Buy |
274,080
+4,497
| +2% | +$115K | 0.02% | 468 |
|
|
2020
Q1 | $6.43M | Sell |
269,583
-9,433
| -3% | -$307K | 0.02% | 476 |
|
|
2019
Q4 | $9.62M | Buy |
279,016
+7,794
| +3% | +$273K | 0.02% | 470 |
|
|
2019
Q3 | $9.66M | Sell |
271,222
-25,827
| -9% | -$872K | 0.02% | 452 |
|
|
2019
Q2 | $9.5M | Buy |
297,049
+14,892
| +5% | +$463K | 0.02% | 519 |
|
|
2019
Q1 | $8.84M | Buy |
282,157
+36,804
| +15% | +$1.12M | 0.02% | 534 |
|
|
2018
Q4 | $6.82M | Sell |
245,353
-3,906
| -2% | -$108K | 0.02% | 518 |
|
|
2018
Q3 | $6.56M | Buy |
249,259
+7,990
| +3% | +$210K | 0.01% | 568 |
|
|
2018
Q2 | $6.23M | Sell |
241,269
-66,674
| -22% | -$1.57M | 0.01% | 563 |
|
|
2018
Q1 | $7.15M | Sell |
307,943
-6,907
| -2% | -$160K | 0.01% | 491 |
|
|
2017
Q4 | $8.21M | Sell |
314,850
-1,928,321
| -86% | -$51.1M | 0.02% | 482 |
|
|
2017
Q3 | $62.4M | Buy |
+2,243,171
| New | +$67.5M | 0.11% | 174 |
|
Other funds holding DOC
Aberdeen Group's DOC Position: Q2 2026 in Review
Aberdeen Group reduced its Healthpeak Properties (DOC) stake by 11% in Q2 2026, selling an estimated $2.54M and leaving 1,065,085 shares worth $22.8M. The position accounts for 0.03% of the portfolio, ranked #406.
Aberdeen Group first reported a position in DOC in Q3 2017 and has held it in 36 quarters since. The position peaked at $62.7M in Q3 2024. 757 funds tracked by Wall St. Rank hold DOC as of Q2 2026.
- Aberdeen Group held 1,065,085 shares of Healthpeak Properties worth $22.8M as of Q2 2026.
- Aberdeen Group sold 135,995 Healthpeak Properties shares in Q2 2026, an estimated $2.54M.
- Healthpeak Properties made up 0.03% of Aberdeen Group's portfolio in Q2 2026, its #406 holding.
- Aberdeen Group first reported a position in Healthpeak Properties in Q3 2017 and has held it in 36 quarters since.
- Aberdeen Group's Healthpeak Properties position peaked at $62.7M in Q3 2024.
- 757 funds tracked by Wall St. Rank held Healthpeak Properties as of Q2 2026.
Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.